ATAD3A and cancer: Not only does ATAD3A promote the resistance of cancer to chemotherapy, but it also negatively affects the therapeutic response of cancer patients to the immune checkpoint inhibitor targeting PD-1/PD-L1 signaling used in combination with chemotherapy [66].